Read more
3:21 PM ยท 11 December 2025

US100 loses after Oracle earnings ๐Ÿ“‰

US100
Indices
-
-

Gains following the Fed’s decision evaporated quickly as disappointing results from Oracle (ORCL.US) soured sentiment and hit technology stocks hard. Investors shifted their focus away from the prospect of further rate cuts and back toward tech-sector fundamentals, where concerns are resurfacing about stretched valuations, excessive spending on AI infrastructure, and slow returns on invested capital. AI-linked stocks came under pressure after Oracle’s earnings release: Nvidia and AMD slipped about 1%, while CoreWeave dropped nearly 4%.

  • Nasdaq 100 (US100) futures fell more than 1.5% at the day’s low, dragging Asian tech stocks lower. Currently, the US100 is down roughly 0.8%, while the US500 is retreating by 0.6%. In Asia, shares of SoftBank strongly tied to OpenAI sank more than 8% in Tokyo.
  • Oracle shares plunged over 10% in after-hours trading after second fiscal quarter revenue fell well short of market expectations. The weakness is particularly painful given Oracle’s positioning in the AI boom and growing concerns about inflated valuations across the sector.
  • The company revealed a surge in spending on AI data centers and hardware infrastructure, but results suggest that monetization is progressing more slowly than investors hoped. The imbalance between rising costs and slower revenue growth is raising fresh concerns.
  • Bitcoin is down more than 2.5% today, erasing its post-Fed jump from $94,000 back toward $90,000 — a clear sign of risk aversion returning to the market.

The US100 is attempting to stabilize after the sell-off and has moved back above the 200-hour EMA. Despite late-autumn volatility, the Nasdaq 100 is still up nearly 22% this year, while the MSCI Global Equity Index remains more than 20% higher year-to-date, on track for its best annual performance since 2019.

Source: xStation5

Bitcoin erased Fed-related gains almost instantly as US futures rolled over.

Source: xStation5

Oracle worries Wall Street - but should it?

Instead of calming markets, Oracle’s quarterly report reignited debate over whether AI-infrastructure spending has gone too far. Is the concern justified? Recall that in September, Oracle secured a high-profile five-year, $300 billion compute-capacity contract with OpenAI, sending the stock sharply higher in a single session. Following that announcement, Larry Ellison briefly became the richest person in the world. Over the past six months, the company signed around $385 billion in additional contracts, including with Nvidia and Meta Platforms yet optimism around the stock is fading.

  • In the latest quarter, Oracle delivered earnings of $2.26 per share, far above the $1.64 forecast, but quarterly revenue came in at $16.06 billion, missing expectations of $16.2 billion. Despite the disappointment, Oracle still posted 14% revenue growth and a remarkable 68% jump in Oracle Cloud Infrastructure (OCI) sales to $4.1 billion, while total cloud revenue reached $7.98 billion (vs. $7.92 billion expected). Still, that wasn’t enough to satisfy Wall Street.
  • Net income rose to $6.14 billion from $3.15 billion a year earlier. Software revenue fell 3% to $5.88 billion, below the expected $6.06 billion. Despite higher net income, free cash flow in the November quarter was a negative $10 billion — far worse than the projected -$5.2 billion.
  • For the next quarter, the company expects earnings of $1.70–1.74 per share and revenue growth of 19–21% year-over-year. The consensus stood at $1.72 per share and $16.87 billion in revenue, implying around 19% growth. Oracle also raised its planned annual CAPEX by $15 billion to $50 billion — a 40% increase — compared with $21 billion in the previous fiscal year.
  • Signed but not yet recognized revenue surged to $528 billion, an astonishing 438% increase year-over-year and a notable jump from $455 billion last quarter. The pipeline is enormous and still expanding, and Oracle expects an additional $4 billion in revenue in fiscal 2027.
  • OpenAI has committed to spending more than $300 billion on Oracle’s infrastructure over five years, a cornerstone of Oracle’s position in the AI ecosystem. The challenge for markets is that this aggressive build-out of data centers and AI infrastructure has boosted orders — but also significantly increased the company’s debt burden.
  • Oracle insists it will maintain its investment-grade credit rating and says part of the financing will come from customers supplying their own chips for installation in Oracle’s data centers, as well as suppliers offering chips under leasing arrangements. New commitments lifted projected annual capital expenditures to around $50 billion (up from $35 billion estimated in September), compared with $21 billion last fiscal year.
  • The company addressed analyst reports suggesting Oracle may need more than $100 billion to complete its infrastructure expansion. Oracle argues its real financing needs will be lower.

During the quarter, Oracle appointed Clay Magouyrk and Mike Sicilia as its new CEOs and introduced a suite of AI agents designed to automate finance, HR and sales processes. GAAP and adjusted earnings were boosted by a $2.7 billion pre-tax gain from the sale of its stake in chipmaker Ampere, which SoftBank agreed to acquire for $6.5 billion. Oracle explained that it sold Ampere because producing its own chips is no longer seen as strategically necessary. The company now aims to use whichever chips its customers prefer. Oracle shares fell 23% in November the stock’s worst monthly performance since 2001. The price remains roughly 30% below the September peak, though it is still up more than 30% year-to-date, outperforming the Nasdaq.

Source: xStation5

Source: XTB Research, Bloomberg Finance L.P.

11 December 2025, 10:46 PM

Daily summary: SILVER at a new ATH, EURUSD at its highest since October

11 December 2025, 7:56 PM

NATGAS drops over 7% ๐Ÿšจ

11 December 2025, 7:31 PM

BREAKING: NATGAS unmoved afer higher than expected EIA inventory draw

11 December 2025, 4:29 PM

DE40: DAX slightly loses๐Ÿ“‰Carl Zeiss Meditec under pressure after earnings

The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.

Join over 2 000 000 investors from around the world